BioMarin Pharmaceutical/ US09061G1013 /
| 7/8/2025 7:48:05 PM | Chg. +0.74 | Volume | Bid7:48:05 PM | Ask7:48:07 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 58.15USD | +1.28% | 56,485 Turnover: 3.31 mill. |
58.12Bid Size: 100 | 58.17Ask Size: 100 | 11.17 bill.USD | - | 25.88 |
Fundamentals
| FY 2024 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 2.25 USD | 152.81% |
| EPS Diluted: | 2.21 USD | 154.02% |
| Revenues per Share: | 14.96 USD | 16.67% |
| Book Value per Share: | 29.66 USD | 13.01% |
| Cash Flow per Share: | 3.00 USD | 255.73% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 2,853.92 USD | 17.97% |
| Net Income: | 426.86 USD | 154.62% |
| Operating Cash Flow: | 572.84 USD | - |
| Cash and Cash Equivalents: | 942.84 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 25.88 | 29.21 |
| P/S Ratio: | 3.89 | 4.39 |
| P/BV ratio: | 1.96 | 2.22 |
| P/CF Ratio: | 19.39 | 21.89 |
| PEG: | 0.17 | 0.19 |
| Earnings Yield: | 3.86% | 3.42% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 11.17 bill. USD | 12.54 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 191.78 mill. | |
Profitability
| Gross Profit Margin: | 79.67% |
| EBIT Margin: | 16.97% |
| Net Profit Margin: | 14.96% |
| Return on Equity: | 7.54% |
| Return on Assets: | 6.11% |
Financial Strength
| Liquidity I / Cash Ratio: | 1.55% |
| Liquidity II / Quick Ratio: | 2.64% |
| Liquidity III / Current Ratio: | 5.33% |
| Debt / Equity Ratio: | 0.11% |
| Dynam. Debt / Equity Ratio: | 232.34% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 12/31/2024 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
